Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.2%

1 terminated/withdrawn out of 46 trials

Success Rate

97.5%

+11.0% vs industry average

Late-Stage Pipeline

20%

9 trials in Phase 3/4

Results Transparency

5%

2 of 39 completed trials have results

Key Signals

4 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
24(53.3%)
Phase 3
9(20.0%)
Phase 2
8(17.8%)
N/A
4(8.9%)
45Total
Phase 1(24)
Phase 3(9)
Phase 2(8)
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (46)

Showing 20 of 46 trials
NCT07548853Phase 3Not Yet Recruiting

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis

Role: lead

NCT07548840Phase 3Not Yet Recruiting

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Role: lead

NCT07285291Phase 3Recruiting

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Role: lead

NCT07231029Phase 1Recruiting

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

Role: lead

NCT07285304Phase 3Recruiting

A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Role: lead

NCT06745531Phase 3Completed

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Role: lead

NCT07084961Phase 1Completed

A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects

Role: lead

NCT06745518Phase 2Completed

A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Role: lead

NCT04821271Phase 2Terminated

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

Role: collaborator

NCT06837155Phase 1Completed

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

Role: lead

NCT06849778Phase 1Completed

An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis

Role: lead

NCT06837142Phase 1Completed

A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects

Role: lead

NCT05461352Phase 3Completed

Long-Term Study of TS-142 in Patients with Insomnia

Role: lead

NCT04169893Phase 1Completed

A Phase I Study of TS-142 in Healthy Participants (Single Doses)

Role: lead

NCT05819710Phase 1Completed

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

Role: lead

NCT05707897Phase 1Completed

A Food Effect Study of TS-142 in Healthy Subjects

Role: lead

NCT04979572Phase 1Completed

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

Role: lead

NCT04746105Phase 1Completed

A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea.

Role: lead

NCT05624944Phase 1Completed

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

Role: lead

NCT03572985Not ApplicableCompleted

Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #3

Role: lead